Back to Journals » OncoTargets and Therapy » Volume 10

Increased histone deacetylase 6 expression serves as a favorable prognostic factor for diffuse large B-cell lymphoma

Authors Lin X, Cai L, Qian Z, Wang C, Sun N, Sun X, Huang H, Guo W, Lin H, Yao R

Received 31 May 2017

Accepted for publication 5 September 2017

Published 24 October 2017 Volume 2017:10 Pages 5129—5136

DOI https://doi.org/10.2147/OTT.S142974

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Geoffrey Pietersz

Xiao-Ji Lin,1 Li-Meng Cai,2 Zi-Jun Qian,2 Chen-Yi Wang,2 Ni Sun,1 Xiao-Hai Sun,1 He Huang,1 Wen-Jian Guo,1 Hai-Yan Lin,1 Rong-Xin Yao1

1Department of Haematology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, 2Science and Technology of Students Association, The Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China

Objective: This study aims to investigate ectopic expression of histone deacetylase 6 (HDAC6) in diffuse large B-cell lymphoma (DLBCL).
Methods: This study analyzed patients with DLBCL (n=132) and reactive lymph node hyperplasia (n=32) diagnosed in our hospital from December 2007 to May 2016. Correlation between HDAC6 expression and clinical pathologic features was analyzed by χ2 test. The significant differences between the 5-year overall survival (OS) or progression-free survival (PFS) and high HDAC6 expression as well as DLBCL clinic-pathological features including age, International Prognostic Index (IPI) score, Eastern Cooperative Oncology Group score, lactate dehydrogenase (LDH), and germinal center B-cell-like were assessed by univariate and multivariate analyses.
Results: HDAC6 high-expression percentage in DLBCL was significantly higher than that in the control group. The proportion of IPI score of 0–2, 5-year OS, and PFS in the high-expression group, which had lower percentage of patients with increased LDH and β2-microglobulin, were significantly higher than those in the low-expression group. Moreover, HDAC6 mRNA expression in HDAC6 protein low expression was markedly lower than that in protein high expression. The multivariate analysis demonstrated that HDAC6 high expression was an independent prognostic factor for patients with DLBCL.
Conclusion: HDAC6 high expression might be a prognostic factor for DLBCL.

Keywords: diffuse large B-cell lymphoma, HDAC6, prognosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]